Prof. Lee was invited to the 6^th Gaucher Regional Forum -virtual edition, where he talked about the biosimilarity in the orphan world, particularly in the drug development for Gaucher disease. Prof. Lee also moderated the session. A year ago, Prof. Lee joined the 5^th of its kind, held in Kuala Lumpur, Malaysia. 

The Forum entailed a series of dynamic and exciting discussion around the diagnosis, patient management and the safety and well-being of patients with Gaucher Disease. In his speech, Prof. Lee contrasted the differences between small molecule drugs and biologics, and how these differences could translate into something every clinician has to understand when she prescribes a biosimilar to her patients. Prof. Lee went further to explain why intended copies are not true biosimilars although almost all of them have been promoted and marketed as they were. For example, Abcertin by ISU ABXIS is not a true biosimilar to its reference biologic, which is imiglucerase by Genzyme®. Knowing the difference between true biosimilars and intended copies is very important not only for every practicing physician, patient, but for regulators to ensure each patient gets a biologic of high quality, which underwent the regulatory review and scrutiny.